{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:02:36Z","timestamp":1788134556637,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014337","name":"Menarini Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients with chronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidence of atrial fibrillation (AF) compared with no-Ran prescription (No-Ran).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The original population (N = 6.1 million) derived from the databases of the Italian National Health System; information concerned hospitalizations with the related diagnoses, drug therapy, follow-up clinical events and visits. Patients hospitalized between 2011 and 2020 for any cause and discharged with an ICD-9-CM CCS code were studied if AF had not been diagnosed before. The follow-up duration was 4.4 and 5.0 years for the Ran and the No-Ran cohorts, respectively. Study subjects were 171 015 (mean age: 72 years; men: 66%; Ran: N = 22 207; No-Ran: N = 148 808). After propensity score matching, Ran (N = 6384) and No-Ran (N = 25 536) cohorts were similar for age, sex, comorbidities and drug therapy. AF incidence during follow-up was 5.3% and 9.6% in the Ran and in the No-Ran cohorts, respectively, with a 41% drug-related lower risk of arrhythmia development in the Cox model (HR = 0.59, 95% CI: 0.53\u20130.67, P &amp;lt; 0.001). Also, Ran correlated with reduced incidence of brady-arrhythmias (P = 0.001) and ventricular tachy-arrhythmias (P = 0.049), and with lower mortality (P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study, performed in a subset of the Italian CCS population, showed that Ran therapy was safe and associated with a long-term reduced AF incidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf074","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:47:57Z","timestamp":1759232877000},"page":"674-681","source":"Crossref","is-referenced-by-count":3,"title":["Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6950-3875","authenticated-orcid":false,"given":"Stefano","family":"Fumagalli","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Unit of Internal and Specialist Medicine, University of Florence and AOU Careggi , Viale G. Pieraccini 6, Florence 50139 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Dovizio","sequence":"additional","affiliation":[{"name":"Department of Innovative Technologies in Medicine & Dentistry, \u2018G. D\u2019 Annunzio\u2019 University of Chieti-Pescara , Chieti 66100 ,","place":["Italy"]},{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research , Bologna 40137 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research , Bologna 40137 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[{"name":"CliCon S.r.l. Societ\u00e0 Benefit, Health, Economics & Outcomes Research , Bologna 40137 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Santamaria","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit, University of Florence and AOU Careggi , Florence 50134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Spanalatte","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit, University of Florence and AOU Careggi , Florence 50134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-5049","authenticated-orcid":false,"given":"Carlo","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"University of Campania \u2018Luigi Vanvitelli\u2019 , Naples 80138 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Cagnoni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit, University of Florence and AOU Careggi , Florence 50134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Tariello","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit, University of Florence and AOU Careggi , Florence 50134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Innovative Treatment, Drug Research and Child Health\u2014\u2018NEUROFARBA\u2019, Section of Pharmacology and Toxicology, University of Florence , Florence 50139 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence 50134 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025121518520635000_pvaf074-B1","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025121518520635000_pvaf074-B2","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","article-title":"Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation acute coronary syndrome thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"2025121518520635000_pvaf074-B3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2023.09.066","article-title":"The role of ranolazine in heart failure-current concepts","volume":"209","author":"Kourampi","year":"2023","journal-title":"Am J Cardiol"},{"key":"2025121518520635000_pvaf074-B4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.yjmcc.2006.08.012","article-title":"Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts","volume":"41","author":"Fraser","year":"2006","journal-title":"J Mol Cell Cardiol"},{"key":"2025121518520635000_pvaf074-B5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(08)61554-8","article-title":"Ranolazine for chronic stable angina","volume":"372","author":"Nash","year":"2008","journal-title":"Lancet"},{"key":"2025121518520635000_pvaf074-B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/ph15010031","article-title":"Ranolazine: an old drug with emerging potential; lessons from Pre-clinical and clinical investigations for possible repositioning","volume":"15","author":"Rouhana","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025121518520635000_pvaf074-B7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3389\/fphar.2019.01367","article-title":"Antiarrhythmic properties of ranolazine: inhibition of atrial fibrillation associated TASK-1 potassium channels","volume":"10","author":"Ratte","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025121518520635000_pvaf074-B8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/europace\/eus380","article-title":"Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation","volume":"15","author":"Verrier","year":"2013","journal-title":"Europace"},{"key":"2025121518520635000_pvaf074-B9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (ranolazine in atrial fibrillation following an ELectricaL CardiOversion) study","volume":"12","author":"De Ferrari","year":"2015","journal-title":"Heart rhythm"},{"key":"2025121518520635000_pvaf074-B10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/pace.13048","article-title":"Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone-only therapy","volume":"40","author":"Tsanaxidis","year":"2017","journal-title":"Pacing Clin Electrophysiol"},{"key":"2025121518520635000_pvaf074-B11","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025121518520635000_pvaf074-B12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1060028016673073","article-title":"Novel use of ranolazine as an antiarrhythmic agent in atrial fibrillation","volume":"51","author":"White","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2025121518520635000_pvaf074-B13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2023.10.010","article-title":"Anticoagulation in atrial fibrillation. A large real-world update","volume":"121","author":"Bo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025121518520635000_pvaf074-B14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025121518520635000_pvaf074-B15","doi-asserted-by":"crossref","first-page":"20f13681","DOI":"10.4088\/JCP.20f13681","article-title":"Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2025121518520635000_pvaf074-B16","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"2025121518520635000_pvaf074-B17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"2025121518520635000_pvaf074-B18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"2025121518520635000_pvaf074-B19","doi-asserted-by":"crossref","first-page":"4952447","DOI":"10.1155\/2021\/4952447","article-title":"Ranolazine improves glycemic variability and endothelial function in patients with diabetes and chronic coronary syndromes: results from an experimental study","volume":"2021","author":"Nusca","year":"2021","journal-title":"J Diabetes Res"},{"key":"2025121518520635000_pvaf074-B20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/europace\/euu217","article-title":"Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial","volume":"17","author":"Scirica","year":"2015","journal-title":"Europace"},{"key":"2025121518520635000_pvaf074-B21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2016.11.103","article-title":"Ranolazine for rhythm control in atrial fibrillation: a systematic review and meta-analysis","volume":"227","author":"Guerra","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025121518520635000_pvaf074-B22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized classification of cardiac antiarrhythmic drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"2025121518520635000_pvaf074-B23","doi-asserted-by":"crossref","first-page":"euaf076","DOI":"10.1093\/europace\/euaf076","article-title":"Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European heart rhythm association of the ESC","volume":"27","author":"Merino","year":"2025","journal-title":"Europace"},{"key":"2025121518520635000_pvaf074-B24","doi-asserted-by":"crossref","first-page":"e005557","DOI":"10.1161\/CIRCEP.117.005557","article-title":"Mechanisms by which ranolazine terminates paroxysmal but not persistent atrial fibrillation","volume":"12","author":"Ramirez","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025121518520635000_pvaf074-B25","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","article-title":"Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine","volume":"116","author":"Burashnikov","year":"2007","journal-title":"Circulation"},{"key":"2025121518520635000_pvaf074-B26","doi-asserted-by":"crossref","first-page":"H1606","DOI":"10.1152\/ajpheart.00242.2011","article-title":"Mechanisms of atrial-selective block of Na(+) channels by ranolazine: I. Experimental analysis of the use-dependent block","volume":"301","author":"Zygmunt","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025121518520635000_pvaf074-B27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/clc.22425","article-title":"Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial","volume":"38","author":"Gutierrez","year":"2015","journal-title":"Clin Cardiol"},{"key":"2025121518520635000_pvaf074-B28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/eurjpc\/zwac089","article-title":"Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry","volume":"29","author":"Kerneis","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2025121518520635000_pvaf074-B29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/VHRM.S162004","article-title":"All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the platelet-aggregation inhibition: persistence with treatment and cardiovascular events in real world (PIPER) study","volume":"14","author":"Degli Esposti","year":"2018","journal-title":"Vasc Health Risk Manag"},{"key":"2025121518520635000_pvaf074-B30","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force Members","year":"2013","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf074\/64455641\/pvaf074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/8\/674\/64455641\/pvaf074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/8\/674\/64455641\/pvaf074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T23:52:19Z","timestamp":1765842739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/8\/674\/8269306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,12,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf074","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,30]]}}}